肺结节、肺癌筛查与Medicare人群中的肺癌
基于SEER-Medicare数据库,5%样本队列中肺结节(PN)在5年随访期间的发生率为5.0%,初次诊断PN后1年和2年累积肺癌率分别为3.2%和4.7%。肺癌队列中58.1%的PN组患者为局限期,而LDCT筛查组和参照组分别为50.3%和24.4%。
要点
- Medicare人群中肺结节5年发生率约5.0%。
- PN诊断后2年内肺癌累积发生率为4.7%。
- PN组局限期肺癌比例高于LDCT筛查组和参照组。
核心结论
- 肺结节是潜在可治愈肺癌的较常见表现,PN诊断后发现的肺癌多倾向于局限期。
研究设计与样本
- 基于SEER-Medicare数据库的回顾性队列研究,包含5%样本队列(627,547例)和肺癌队列(44,194例)。
主要发现
- 5%样本队列中5.0%出现PN,中位随访5.0年。
- 初次PN诊断后1年和2年累积肺癌率分别为3.2%和4.7%。
- 肺癌队列中PN组、LDCT筛查组和参照组分别占15.7%、2.9%和81.4%。
- PN组、LDCT组和参照组局限期比例分别为58.1%、50.3%和24.4%。
- 全部局限期患者中,PN组占30.0%,LDCT组占4.9%。
关键数值与推荐
- 肺癌队列按诊断前18个月内是否接受LDCT筛查及是否有PN诊断分组。
- PN组、LDCT组和参照组3年肺癌特异性生存率分别为75.0%、75.6%和49.4%。
临床怎么用
- 在Medicare人群中应重视肺结节的随访管理,因其与局限期肺癌诊断相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early detection of lung cancer through management of pulmonary nodules (PNs) may reduce lung cancer mortality. We assessed the relationship between PNs and lung cancer. RESEARCH QUESTION: How common are PNs in the Medicare population? What is the rate of lung cancer after detection of PNs? What is the relative proportion of early-stage lung cancer diagnosed after reporting of PNs vs through low-dose CT (LDCT) scan screening? STUDY DESIGN AND METHODS: Using the Surveillance Epidemiology and End Results Program-Medicare database, we defined two cohorts: those in the 5% sample with ≥ 12 months of Medicare Parts A and B coverage from 2014 through 2019 (5% sample cohort) and those with a diagnosis of lung cancer from 2015 through 2017 with coverage for the prior 18-month period (lung cancer cohort). We defined PNs as chest CT scans with accompanying codes of 793.11 (International Classification of Diseases [ICD], Ninth Revision) or R91.1 (ICD, Tenth Revision) denoting a solitary PN. Patients in the lung cancer cohort were classified by whether they had undergone LDCT scan screening and whether they had a diagnosis of PN or neither (reference) within 18 months before diagnosis. We compared cancer stage and survival across groups. RESULTS: Of 627,547 patients in the 5% sample cohort, 5.0% demonstrated PNs over median of 5.0 years of follow-up. Cumulative 1- and 2-year lung cancer rates after initial PN diagnosis were 3.2% and 4.7%, respectively. Of 44,194 patients in the lung cancer cohort, 15.7%, 2.9%, and 81.4% were in the PN, LDCT scan, and reference groups, respectively. Of patients in the PN, LDCT scan, and reference groups, 58.1%, 50.3%, and 24.4% respectively, had disease of a localized stage. Among all patients with localized disease, 30.0% and 4.9% were in the PN and LDCT scan and groups, respectively. Three-year lung cancer-specific survival rates were 75.0%, 75.6%, and 49.4% for the PN, LDCT scan, and reference groups. INTERPRETATION: Patients with lung cancer who received a diagnosis after identification of PNs tended to have localized disease. Of all patients with localized disease, almost one-third had PNs that were diagnosed previously, compared with 5% of patients who had undergone LDCT scan screening. PNs represent a relatively common presentation of potentially curable lung cancer.
引用
- Pinsky P, Miller E, Faris N, et al. Pulmonary Nodules, Lung Cancer Screening, and Lung Cancer in the Medicare Population. Chest. 2022. PMID: 36529155. doi:10.1016/j.chest.2022.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。